Biological E to start COVID vaccine Phase III trial, production from August
New Delhi: India's Biological E. Ltd will soon start Phase III trials of its COVID-19 vaccine and plans producing 75 million to 80 million doses a month from August, its managing director told Reuters on Friday.
The company has developed the vaccine with Baylor College of Medicine in Houston and Dynavax Technologies Corp. Late last month it received approval from India's drug regulator to conduct a Phase III clinical trial, which Managing Director Mahima Datla said would begin soon.
India, battling the world's worst jump in coronavirus infections, has partially or fully immunized only about 10% of its 1.35 billion people. It has administered a total of 163 million doses of the AstraZeneca shot and a domestically made one called Covaxin.
The country has also received doses of the Sputnik V vaccine from Russia though it has not been launched yet in the country. India has also urged Pfizer/BioNTech and Moderna to sell their shots to the country.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.